Thursday, June 06, 2013 9:54:22 AM
June 6, 9:30 AM ET
UBS likes the risk/reward profile for Momenta Pharmaceuticals (MNTA +4%) as analyst Ami Fadi says management's rhetoric indicates approval for generic Copaxone may come in time for 2015 patent expirations.
http://seekingalpha.com/currents/post/1068791
Advances in Domestic Heavy Rare Earth Minerals Production Essential for North American Defense Stockpiles • ALOY • Mar 18, 2026 9:00 AM
ECGI Advances $10M Mortgage Tokenization Pilot as SEC Interpretation Adds Clarity • ECGI • Mar 18, 2026 8:45 AM
ECGI Advances Mortgage Tokenization Pilot as Institutional Market Rails Continue to Develop • ECGI • Mar 17, 2026 8:30 AM
Record Gold Prices Reshape Economics of New Mine Development • SNWGF • Mar 16, 2026 10:46 AM
Cannabix Technologies Announces Commercial Launch of Marijuana Breath Test (MBT) • BLOZF • Mar 16, 2026 8:37 AM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
